AstraZeneca’s Fasenra Receives EU Approval for Eosinophilic Granulomatosis with Polyangiitis
Shots:
- The EU has approved Fasenra (benralizumab) as an add-on therapy for treating r/r eosinophilic granulomatosis with polyangiitis (EGPA) in adults
- The approval was based on a P-III (MANDARA) trial assessing the safety & efficacy of Fasenra (single 30mg, SC, Q4W) vs mepolizumab (separate 100mg, SC, Q4W) for treating adults (n=140) with r/r EGPA, in ratio 1:1
- The study demonstrated remission in 60% of them (comparable to mepolizumab) and 41% vs 26% fully stopped oral corticosteroids (OCS), with safety & tolerability that aligned with the previous profiles of the drugs. Data was published in the NEJM
Ref: AstraZeneca | Image: AstraZeneca
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies. He can be contacted at connect@pharmashots.com
